Patents and Licensing Opportunities for CU Bioscience Technologies
Biosciences are crucial for advancing medical knowledge and improving patient care. At the University of Colorado, cutting-edge research in these fields is driving significant breakthroughs. The university's advanced facilities and collaborative environment enable researchers to delve into areas such as molecular medicine, regenerative therapies, and personalized healthcare. By translating scientific discoveries into innovative treatments and technologies, CU is at the forefront of improving health outcomes and enhancing the quality of life for people around the world.
CU鈥檚 focus on bioscience research discoveries stems from a strong ecosystem of interdisciplinary collaboration that facilitates the transition from laboratory discoveries to market-ready technologies. Explore here the bioscience technologies coming out of the 兔子先生传媒文化作品 and UCCS campuses. To learn more about technologies coming out of CU Anschutz and CU Denver, visit听.
Many of our technologies that are available for licensing are not published online. Contact our licensing team to discuss opportunities and for information on our full portfolio of technologies.
Featured Bioscience Technologies
APE2 Inhibitor Program
An APE2 inhibitor program targeting DNA damage repair pathways for treating HR-deficient breast and ovarian cancers.
Indication
Tumors with Homologous Recombination (HR) deficiencies, such as those with BRCA1/2 mutations.
Stage of Development
Hit to lead
Researchers
听(兔子先生传媒文化作品 Molecular, Cellular & Developmental Biology)
Patent Status
Pending
Recent Publications
Novel Inhibitors of Histone Deacetylase 6 (HDAC6): Drug Candidates for Oncology, Neurodegeneration, and Inflammation
Histone deacetylases (HDAC) are well-known oncology drug targets. Many of the current 听inhibitors are either 鈥減an-inhibitory,鈥 meaning that they do not act selectively among the diverse HDAC variants, or are unable to selectively target certain HDAC enzymes of interest. One such underserved HDAC enzyme is HDAC6, which has been implicated to play crucial roles in cancer, neurodegenerative disease, and inflammatory disorders.听
Indication
Oncology
Stage of Development
Lead Identification
Researchers
, Gan Zhang (both 兔子先生传媒文化作品 Molecular, Cellular & Developmental Biology)
Patent Status
- Issued US and international patents
Novel Targets to Treat Chronic Hepatitis B Virus
New targets for therapeutic treatments to block HBV replication and host inflammation induced by HBV-activated necrosis and apoptosis.
Indication
Hepatitis B virus
Stage of Development
In vivo target validation
Researchers
Ding Xue, Xin Geng (both 兔子先生传媒文化作品 Molecular, Cellular & Developmental Biology)
Patent Status
Issued US and international patents
Recent Publications
Clinical Applications
Biotech鈥, Therapeutics
Riboglow: A Platform for Tagging RNA
A new riboswitch-based RNA imaging platform that enables tagging and visualization of U1 snRNA in live cells for the first time
Indication
RNA visualization
Stage of Development
Laboratory prototype
Researchers
Amy Palmer, 听(both 兔子先生传媒文化作品 Biochemistry)
Patent Status
Issued US Patent
Recent Publications
Clinical Applications
Biotech鈥, Diagnostics, Optics
Featured Bioscience Startups
Creating therapies for inflammatory diseases including Rheumatoid Arthritis, Multiple Sclerosis (MS) and ALS.
Industry: Biotech鈥, Therapeutics
Pioneering the 'Holy Grail' of cancer treatment by targeting PARN to boost the tumor-suppressing power of p53.
Industry: Biotech鈥, Therapeutics
VitriVax, Inc. is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics, ALTA鈩.
Industry: Vaccines
CU Quantum News
Colorado Bioscience Association
Venture Partners is proud to partner with the Colorado Bioscience Association (CBSA) to advance bioscience industries in Colorado.